282 related articles for article (PubMed ID: 35708342)
1. The use of short-acting bronchodilators and cost burden of asthma across Global Initiative for Asthma-based severity levels: Insights from a large US commercial and managed Medicaid population.
Pollack M; Gandhi H; Tkacz J; Lanz M; Lugogo N; Gilbert I
J Manag Care Spec Pharm; 2022 Aug; 28(8):881-891. PubMed ID: 35708342
[No Abstract] [Full Text] [Related]
2. Incremental cost burden among patients with severe uncontrolled asthma in the United States.
Burnette A; Wang Y; Rane PB; Chung Y; Princic N; Park J; Llanos JP; Lindsley AW; Ambrose CS
J Manag Care Spec Pharm; 2023 Jul; 29(7):825-834. PubMed ID: 37404066
[No Abstract] [Full Text] [Related]
3. Short-Acting Beta-2-Agonist Exposure and Severe Asthma Exacerbations: SABINA Findings From Europe and North America.
Quint JK; Arnetorp S; Kocks JWH; Kupczyk M; Nuevo J; Plaza V; Cabrera C; Raherison-Semjen C; Walker B; Penz E; Gilbert I; Lugogo NL; van der Valk RJP;
J Allergy Clin Immunol Pract; 2022 Sep; 10(9):2297-2309.e10. PubMed ID: 35364341
[TBL] [Abstract][Full Text] [Related]
4. Patient Support Program Increased Medication Adherence with Lower Total Health Care Costs Despite Increased Drug Spending.
Brixner D; Rubin DT; Mease P; Mittal M; Liu H; Davis M; Ganguli A; Fendrick AM
J Manag Care Spec Pharm; 2019 Jul; 25(7):770-779. PubMed ID: 31081461
[TBL] [Abstract][Full Text] [Related]
5. Annual costs among patients with major depressive disorder and the impact of key clinical events.
Cutler AJ; Keyloun KR; Higa S; Park J; Bonafede M; Gillard P; Jain R
J Manag Care Spec Pharm; 2022 Dec; 28(12):1335-1343. PubMed ID: 36427344
[No Abstract] [Full Text] [Related]
6. Real-world patterns and implications of short-acting β
Lugogo N; Gilbert I; Tkacz J; Gandhi H; Goshi N; Lanz MJ
Ann Allergy Asthma Immunol; 2021 Jun; 126(6):681-689.e1. PubMed ID: 33515710
[TBL] [Abstract][Full Text] [Related]
7. Prompt initiation of triple therapy following hospitalization for a chronic obstructive pulmonary disease exacerbation in the United States: An analysis of the PRIMUS study.
Evans KA; Pollack M; Portillo E; Strange C; Touchette DR; Staresinic A; Patel S; Tkacz J; Feigler N
J Manag Care Spec Pharm; 2022 Dec; 28(12):1366-1377. PubMed ID: 36427341
[No Abstract] [Full Text] [Related]
8. Clinical and economic characterization of mild, moderate, and severe systemic lupus erythematosus: Real-world observation across payer channels in the United States.
Wu SS; Perry A; Tkacz J; Bryant G
J Manag Care Spec Pharm; 2023 Sep; 29(9):1010-1020. PubMed ID: 37610115
[No Abstract] [Full Text] [Related]
9. Evaluation of Budesonide-Formoterol for Maintenance and Reliever Therapy Among Patients With Poorly Controlled Asthma: A Systematic Review and Meta-analysis.
Beasley R; Harrison T; Peterson S; Gustafson P; Hamblin A; Bengtsson T; Fagerås M
JAMA Netw Open; 2022 Mar; 5(3):e220615. PubMed ID: 35230437
[TBL] [Abstract][Full Text] [Related]
10. Health-related quality of life in GALAHAD: A multicenter, open-label, phase 2 study of niraparib for patients with metastatic castration-resistant prostate cancer and DNA-repair gene defects.
Smith MR; Sandhu S; George DJ; Chi KN; Saad F; Thiery-Vuillemin A; Stàhl O; Olmos D; Danila DC; Gafanov R; Castro E; Moon H; Joshua AM; Mason GE; Espina BM; Liu Y; Lopez-Gitlitz A; Francis P; Bevans KB; Fizazi K
J Manag Care Spec Pharm; 2023 Jul; 29(7):758-768. PubMed ID: 37404070
[No Abstract] [Full Text] [Related]
11. Economic Burden of Illness Among Patients with Severe Asthma in a Managed Care Setting.
Chastek B; Korrer S; Nagar SP; Albers F; Yancey S; Ortega H; Forshag M; Dalal AA
J Manag Care Spec Pharm; 2016 Jul; 22(7):848-61. PubMed ID: 27348285
[TBL] [Abstract][Full Text] [Related]
12. Economic Burden of Patients with Inadequate Response to Targeted Immunomodulators for Rheumatoid Arthritis.
Strand V; Tundia N; Song Y; Macaulay D; Fuldeore M
J Manag Care Spec Pharm; 2018 Apr; 24(4):344-352. PubMed ID: 29578852
[TBL] [Abstract][Full Text] [Related]
13. Evaluation of clinical characteristics, health care resource utilization, and cost outcomes of hemophilia A carriers and noncarriers in the United States: A real-world comparative analysis.
Xing S; Batt K; Kuharic M; Bullano M; Caicedo J; Chakladar S; Markan R; Farahbakhshian S
J Manag Care Spec Pharm; 2023 Jun; 29(6):626-634. PubMed ID: 37276033
[No Abstract] [Full Text] [Related]
14. Sustained long-term benefits of patient support program participation in immune-mediated diseases: improved medication-taking behavior and lower risk of a hospital visit.
Fendrick AM; Brixner D; Rubin DT; Mease P; Liu H; Davis M; Mittal M
J Manag Care Spec Pharm; 2021 Aug; 27(8):1086-1095. PubMed ID: 33843252
[No Abstract] [Full Text] [Related]
15. Patient Outcomes, Health Care Resource Use, and Costs Associated with High Versus Low HEDIS Asthma Medication Ratio.
Luskin AT; Antonova EN; Broder MS; Chang E; Raimundo K; Solari PG
J Manag Care Spec Pharm; 2017 Nov; 23(11):1117-1124. PubMed ID: 29083971
[TBL] [Abstract][Full Text] [Related]
16. Patterns of rescue and maintenance therapy claims surrounding a clinical encounter for an asthma exacerbation.
Lanz MJ; Gilbert IA; Gandhi HN; Pollack M; Tkacz JP; Lugogo NL
Ann Allergy Asthma Immunol; 2023 Oct; 131(4):458-465.e1. PubMed ID: 37343824
[TBL] [Abstract][Full Text] [Related]
17. Health Care Resource Utilization and Exacerbation Rates in Patients with COPD Stratified by Disease Severity in a Commercially Insured Population.
Wallace AE; Kaila S; Bayer V; Shaikh A; Shinde MU; Willey VJ; Napier MB; Singer JR
J Manag Care Spec Pharm; 2019 Feb; 25(2):205-217. PubMed ID: 30698096
[TBL] [Abstract][Full Text] [Related]
18. Asthma control in the United States: relationships between short-acting β
Chupp G; Murphy KR; Gandhi HN; Gilbert I; Bleecker ER
Ann Allergy Asthma Immunol; 2024 May; ():. PubMed ID: 38740134
[TBL] [Abstract][Full Text] [Related]
19. Comparison of Health Care Costs Among Patients with Psoriasis Initiating Ixekizumab, Secukinumab, or Adalimumab.
Blauvelt A; Shi N; Zhu B; Burge R; Malatestinic WN; Lin CY; Lew CR; Zimmerman NM; Goldblum OM; Murage MJ
J Manag Care Spec Pharm; 2019 Dec; 25(12):1366-1376. PubMed ID: 31778621
[TBL] [Abstract][Full Text] [Related]
20. Comparison of health care costs and resource utilization for commonly used proteasome inhibitor-immunomodulatory drug-based triplet regimens for the management of patients with relapsed/refractory multiple myeloma in the United States.
Sanchez L; Chari A; Cheng M; Cherepanov D; DerSarkissian M; Huang F; Stull DM; Dabora J; Young M; Noga SJ; Pi S; Zhang M; Banatwala A; Duh MS; Ailawadhi S
J Manag Care Spec Pharm; 2023 Nov; 29(11):1205-1218. PubMed ID: 37776124
[No Abstract] [Full Text] [Related]
[Next] [New Search]
